Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02697630 | Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye(PEMDAC) | completed | Phase 2 | 29 | Vastra Gotaland RegionOTHER_GOV | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02223819 | Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy | completed | Phase 2 | 34 | Columbia UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06152367 | Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients | completed | Phase 1 / Phase 2 | 90 | University of ChileOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02799901 | Nivolumab Plus Radiotherapy in Advanced Melanoma(NIRVANA) | completed | Phase 2 | 72 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT03089606 | Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker | completed | Phase 2 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02407171 | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | completed | Phase 1 / Phase 2 | 61 | Yale UniversityOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT04059224 | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma(TraMel-WT) | completed | Phase 2 | 45 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02403778 | Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | completed | Phase 2 | 10 | University of Colorado, DenverOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT02515227 | Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab(Mel64) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT01152788 | Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma | completed | Phase 2 | 64 | NCIC Clinical Trials GroupNETWORK | 2 | Aug 22, 2023 | clinicaltrials |
| NCT00336986 | Efficacy Study of IL-21 to Treat Metastatic Melanoma | completed | Phase 2 | 54 | Novo Nordisk A/SINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00053781 | Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma | completed | Phase 2 | 18 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00514085 | Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma | completed | Phase 2 | 40 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT00591370 | Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT00700882 | Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 81 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT00049530 | PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 32 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00071981 | Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 175 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT00003308 | Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 22, 2023 | clinicaltrials |
| NCT00003601 | Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome | completed | Phase 2 | 38 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03973151 | Study of HL-085 in NRAS Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 42 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05217303 | HL-085 in NRAS-mutated Advanced Melanoma | completed | Phase 2 | 100 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT01502293 | Trial of pIL-12 Electroporation Malignant Melanoma(IL-12MEL) | completed | Phase 2 | 51 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03171064 | Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment(Sportivumab) | completed | Phase 2 | 39 | University Hospital HeidelbergOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT02570308 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | completed | Phase 1 / Phase 2 | 146 | Immunocore LtdINDUSTRY | 5 | Mar 21, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT01993719 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02821182 | A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. | completed | Phase 2 | 20 | University Hospital, GhentOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02731729 | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | completed | Phase 2 | 20 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02038348 | Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study | completed | Phase 2 | 5 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01807182 | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02115139 | GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases(GRAY-B) | completed | Phase 2 | 58 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT00518206 | Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | completed | Phase 2 | 46 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT00520299 | Study of ADI-PEG 20 in Patients With Advanced Melanoma | completed | Phase 1 / Phase 2 | 31 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03396952 | Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | completed | Phase 2 | 27 | University of California, San FranciscoOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT00199901 | Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | completed | Phase 2 | 111 | Ludwig Institute for Cancer ResearchOTHER | 3 | Oct 12, 2022 | clinicaltrials |
| NCT00679289 | Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | completed | Phase 2 | 36 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04172454 | Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03834623 | Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02334735 | A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence | completed | Phase 2 | 36 | Nina BhardwajOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02089685 | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | completed | Phase 1 / Phase 2 | 295 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT01835145 | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Dec 8, 2023source: clinicaltrials